Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Diabetic Peripheral Neuropathy: early-phase trial registry

5 of 18 indexed Diabetic Peripheral Neuropathy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #953 of 28,707 conditions by registered trial count.

18 US clinical trials · 5 currently recruiting · #953 of 28,707 conditions by registered trial count

Diabetic Peripheral Neuropathy: 18 US clinical trials tracked, 5 recruiting.

Diabetic Peripheral Neuropathy is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Florida Institute for Human and Machine Cognition, running 2 of these trials.

Enrollment posture brief

Registry condition diabetic-peripheral-neuropathy

OPEN 5 | RECR 28% | LATE 2 | EARLY 4 | RANK #953 | SPON 2

Nearest open-share peer: Neurofibromatosis Type 1 (28% recruiting · 18 trials)

Diabetic Peripheral Neur (th…28%Arrhythmias, Cardiac27.8%Androgenetic Alopecia16.7%Anemia, Sickle Cell16.7%Acquired Immunodeficiency Sy5.6%
Open-enrollment share among volume-matched conditions near Diabetic Peripheral Neuropathy

Diabetic Peripheral Neuropathy lists 5 open slots (28% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Diabetic Peripheral Neuropathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Diabetic Peripheral Neuropathy is recruiting below its size-band peers.

    5 of 18 indexed trials (27.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Diabetic Peripheral Neuropathy trials is spread across many organizations.

    Florida Institute for Human and Machine Cognition accounts for 2 of 18 trials (11.1%). 16 distinct sponsors appear on at least one study for this condition label.

  3. Most Diabetic Peripheral Neuropathy trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 18 trials that report a genuine target (sentinel values excluded). 12 of those (66.7%) plan for fewer than 100 participants.

  4. Diabetic Peripheral Neuropathy research is mostly interventional.

    15 interventional and 3 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 24Phase 32

Open and recent trials

18 total, page 1 of 1

RECRUITING NA 60 participants

Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy

Ohio State University

NCT06287736

RECRUITING NA 60 participants

Balance Control and Recovery in Diabetes Peripheral Neuropathy

Lisa Griffin

NCT06544876

RECRUITING NA 50 participants

Walking Function in Diabetic Peripheral Neuropathy

Florida Institute for Human and Machine Cognition

NCT05965336

RECRUITING NA 25 participants

Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy

Florida Institute for Human and Machine Cognition

NCT06591780

RECRUITING NA 15 participants

Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy

VA Office of Research and Development

NCT04658693

ACTIVE NOT RECRUITING Phase 2 142 participants

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Novo Nordisk A/S

NCT06797869

COMPLETED Phase 3 460 participants

A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NCT01041859

COMPLETED Phase 2 452 participants

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Daiichi Sankyo

NCT01496365

COMPLETED Phase 2 319 participants

Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals

NCT04455633

COMPLETED Phase 2 167 participants

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

Eliem Therapeutics (UK)

NCT04688671

COMPLETED NA 116 participants

Implementation of Telemedicine for Patient With Lower Extremity Wounds

University of California, Davis

NCT04440839

COMPLETED 60 participants

Monitoring Physiologic Parameters in Individuals With Diabetic Peripheral Neuropathy

Orpyx Medical Technologies

NCT05613556

COMPLETED 50 participants

Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy

University of Michigan

NCT00835757

COMPLETED NA 44 participants

Corneal Nerves Function and Structure

VA Office of Research and Development

NCT04222660

COMPLETED NA 44 participants

Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy

Regenesis Biomedical

NCT03077893

COMPLETED Phase 3 44 participants

The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy

Eastern Virginia Medical School

NCT02927951

COMPLETED NA 40 participants

Group Acupuncture Treatment Effects for Painful Diabetic Neuropathy (GATE-PDN)

University of California, San Francisco

NCT02104466

COMPLETED 37 participants

Fall Risk Assessment in People With Diabetic Neuropathy

Stephen D. Jernigan, PT, PhD

NCT01040962

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 2

Named interventions

Most-linked intervention names on Diabetic Peripheral Neuropathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
Plantar Pressure Biofeedback Gait Training Other
2 trials
Clinical Evaluation Other
2 trials
Tapentadol extended release (ER) Drug
1 trials
LX9211 Matching Placebo Drug
1 trials
LX9211 Drug
1 trials
Telemedicine specialty consultation Other
1 trials
Inactive (sham) Provant Therapy System Device
1 trials

US sites by state

Facility locations filed on Diabetic Peripheral Neuropathy trials. A trial with sites in several states counts in each.

California 7 trials
Florida 6 trials
Arizona 5 trials
Ohio 4 trials
Alabama 4 trials
Texas 3 trials
Missouri 3 trials
Georgia 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Diabetic Peripheral Neuropathy page

18 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Peripheral Neuropathy condition card totals 18 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.